Published in Biotech Business Week, January 3rd, 2005
The IMB considers that the current advice provided for these medicines is appropriate and their benefit/risk profile remains positive. The IMB will await the outcome of the E.U. review before implementing any further changes that may be recommended to update the product information for this group of medicines.
The IMB states that this group of medicines has received extensive scrutiny at national and E.U. level and that their use in the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.